Country
|
Target Population
|
No. Positive / No. tested
|
Estimated prevalence
|
Target population %
|
General population (95% CI)
|
U.K. (Wessex) 18;35
|
SpEd population (ages 5-18 years), unknown etiology
|
20/3,738
|
SpEd: 0.5
|
1/5,530 (1/8,992-1/4,007)
|
U.S.A. (Atlanta, Georgia) 28;34
|
SpEd population (ages 7-10 years), regardless of etiology
|
White: 4/1,572
African-American: 3/752
Total: 7/2,740
|
White SpEd: 0.3
African-American SpEd: 0.4
Total SpEd: 0.3
|
White: 1/3,717 (1/7,692-1/1,869)
African-American: 1/2,545 (1/5,208-1/1,289)
Total:1/3,623 (1/5,988-1/2,212)
|
Southwest Netherlands 19
|
Schools and institutes for MR, unknown etiology
|
9/866
|
Mild MR: 2.0 Moderate/Severe MR: 2.4
|
1/6,045 (1/9,981-1/3,851)
|
Hellenic Population of Greece and Cyprus 30
|
Referred clinical population of idiopathic MR
|
8/611
|
MR: 1.3
|
1/4,246 (1/16,440-1/1,333)
|
Australia (Sydney) 95;96
|
Children with MR in SpEd
|
10/472
|
MR: 2.1 Mild MR: 0.6 Moderate/Severe MR: 5.
|
1/4,350 a
|
Southern Häme, Finland 97
|
Adult males (>16 years) registered in the Southern Häme Care Organization with MR, unknown etiology
|
6/344
|
MR: 1.7
|
1/4,400 b
|
U.K. (Coventry) 96;98;99
|
Children with MR in institutions or SpEd
|
6/219
|
MR: 2.7 Mild MR: 1.3 Moderate/Severe MR: 6.7
|
1/4,090 a
|
Poland (Warsaw) 100
|
Males in institutions or SpEd with MR
|
6/201
|
MR: 3.0
|
1/2,857-1/5,882 c
|
U.K. (Wessex) 29
|
SpEd population (ages 5-18 years), unknown etiology
|
4/180
|
SpEd: 2.2
|
1/8,918 d
|
Spain 101
|
Children in SpEd or clinically referred with MR of unknown etiology; no known family history of MR
|
5/180
|
MR: 2.7
|
1/6,200-1/8,200 e
|
Guadeloupe, French West Indies 31
|
SpEd population, unknown etiology
|
11/163
|
SpEd: 6.7
|
1/2,359 (1/4,484-1/276)
|
U.K. (Oxfordshire) 102
|
Children in schools for moderate to severe learning difficulties, unknown etiology
|
4/103
|
MR: 3.9
|
1/4,130 f
|